Illumina Buys Cytogenetic Firm
BlueGnome’s offerings include microarray products for array comparative genome hybridization as well as FISH probes. Illumina’s cytogenetic products consist of SNP arrays, while BlueGnome provides oligonucleotide arrays, manufactured by Agilent, as well as BAC (bacterial artificial chromosome) arrays. According to the UK’s Business Weekly, BlueGnome’s sales grew 65% last year to £11.8 million ($19.0 million = £0.62 = $1). Illumina told investors at a conference that the company has been profitable since 2007. Introduced in 2006, the CytoChip is used in over 200 labs as a first-line test, according to BlueGnome.
San Diego, CA 9/19/12—Illumina has acquired BlueGnome for an undisclosed amount. UK-based BlueGnome provides solutions for the screening of genetic abnormalities associated with developmental delay, cancer and infertility. Products include the 24sure pre-implantation genetic screening test for in vitro fertilization (IVF) and CytoChip for genetic-abnormalities testing associated with developmental delay or complex leukemias. “The BlueGnome acquisition supports Illumina’s goal to be the leader in genomic-based diagnostics and enhances the company’s ability to establish integrated solutions in reproductive health and cancer,” stated Illumina President and CEO Jay Flatley. “BlueGnome is the leader in the rapidly growing IVF market and is well known for their software and comprehensive assay workflows.” BlueGnome founders Nick Haan and Graham Snudden will continue to lead the company.
